Global Genetic Disease Diagnostic Market Growth (Status and Outlook) 2023-2029

Global Genetic Disease Diagnostic Market Growth (Status and Outlook) 2023-2029

Hereditary diseases are those caused by changes in genetic material or controlled by disease-causing genes. Hereditary diseases refer to diseases that are determined wholly or partly by genetic factors, usually congenital or acquired. Be like congenital foolish model, much point to (toe), congenital deafness dumb, hemophilia, these hereditary disease decides to come on completely by genetic factor, and just after be born certain time comes on, want to pass a few years sometimes, more than ten years even ability after decades appears apparent symptom.At present, China has adopted a variety of neonatal disease screening technologies for early diagnosis and treatment of children with genetic diseases without clinical symptoms, effectively reducing the disability rate and mortality rate of children, and greatly reducing the serious harm caused by birth defects to families and society. In recent years, with the rapid development of molecular biology and genomics, genetic testing technology has become the gold standard when it comes to most of the hereditary disease diagnosis, especially in the biochemical or enzymatic method can't make a diagnosis and test results under the condition of not clear, genetic testing is an important means of diagnosis, but in the field of neonatal hereditary disease screening, genetic testing technology is not yet ripe for applications, Gene screening for neonatal deafness has been reported in China.
LPI (LP Information)' newest research report, the “Genetic Disease Diagnostic Industry Forecast” looks at past sales and reviews total world Genetic Disease Diagnostic sales in 2022, providing a comprehensive analysis by region and market sector of projected Genetic Disease Diagnostic sales for 2023 through 2029. With Genetic Disease Diagnostic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetic Disease Diagnostic industry.
This Insight Report provides a comprehensive analysis of the global Genetic Disease Diagnostic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetic Disease Diagnostic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Genetic Disease Diagnostic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetic Disease Diagnostic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetic Disease Diagnostic.
The global Genetic Disease Diagnostic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
In China markets, the core manufacturers of genetic disease diagnostic includes BGI Group, Berry Genomics etc and the top 5 companies hold a share over 40%.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetic Disease Diagnostic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Prenatal Diagnosis
Screening for Single Gene Genetic Disease
Preimplantation Genetic Testing
Others
Segmentation by application
Hospital
Medical Laboratory
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
PerkinElmer
Roche Diagnostics
Bio Rad
Thermo Fisher Scientific
BGI Group
Berry Genomics
Da An Gene Co., Ltd.
Illumina
CapitalBio Technology

Please note: The report will take approximately 2 business days to prepare and deliver.